ArticleNeurology. Genetics2020
Disease duration in autosomal dominant familial Alzheimer disease: A survival analysis.
Article in Neurology. Genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Survival and mortality rates in early onset dementia.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer's disease mutations.Translational psychiatry · 2026Article
- Phenotypic variability in early-onset dementia segregating with a novel APP (p.I718M) variant.Alzheimer's research & therapy · 2025Article
- Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Longitudinal associations between self-reported exercise levels and cognition in ADAD.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Decline in activities of daily living in the rarer dementias.General psychiatry · 2025Review
- Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome.EBioMedicine · 2024Review
- Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research.eLife · 2024Review
- The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.The Lancet. Neurology · 2024Observational
- Observational
- Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [Alzheimer's research & therapy · 2023Article
- Survival in Huntington's disease and other young-onset dementias.International journal of geriatric psychiatry · 2023Article
- Attitudes about involvement in hypothetical clinical trial protocols in Mexican and Mexican-American at risk for autosomal dominant Alzheimer's disease.Alzheimer's research & therapy · 2022Article
- Variability in the type and layer distribution of cortical Aβ pathology in familial Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2022Article
- Machine learning based multi-modal prediction of future decline toward Alzheimer's disease: An empirical study.PloS one · 2022Article
- TheGenes · 2021Article
- Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype.Brain : a journal of neurology · 2021Article
- Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study.Neuropsychologia · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo use survival modeling to estimate disease duration in autosomal dominant familial Alzheimer disease (ADAD) and ascertain whether factors influencing age at onset also affect survival.
methodsSymptomatic mutation carriers (201 presenilin 1 [
resultsEstimated mean survival was 11.6 (10.4-12.9) years and was similar for
conclusionsSurvival is influenced by mutation to a much lesser extent than age at onset. Survival time has increased over time and is longer in atypical presentations. These insights may inform the interpretation of disease-modifying therapy trials in ADAD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.